CCL

Összesen 8 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM042435
Első szerző:Csépány Tünde (neurológus, pszichiáter)
Cím:Cerebral systemic lupus erythematosus / Tünde Csépány, Attila Valikovics, Bela Fülesdi, Emese Kiss, Gyula Szegedi, László Csiba
Dátum:1994
ISSN:0140-6736
Megjegyzések:Korrekcót nyújtottak be a Lancet (1994), 343 : 1512. oldalán, mert a szerzők neve rosszul szerepel a Lancet (1994), 343 : 1103-1104. közleményen.
Tárgyszavak:Orvostudományok Klinikai orvostudományok levél
Arterial redistribution
egyetemen (Magyarországon) készült közlemény
Megjelenés:Lancet. - 343 : 8905 (1994), p. 1103-1104. -
További szerzők:Valikovics Attila Fülesdi Béla (1961-) (aneszteziológus) Kiss Emese (1960-) (belgyógyász, immunológus) Szegedi Gyula (1936-2013) (belgyógyász, immunológus) Csiba László (1952-) (neurológus, pszichiáter)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM117248
035-os BibID:(cikkazonosító)100782 (Scopus)85178352005
Első szerző:de Jonge, Jeroen C.
Cím:Prevention of infections and fever to improve outcome in older patients with acute stroke (PRECIOUS) : a randomised, open, phase III, multifactorial, clinical trial with blinded outcome assessment / de Jonge Jeroen C., Sluis Wouter M., Reinink Hendrik, Bath Philip M., Woodhouse Lisa J., Zweedijk Berber, van de Beek Diederik, Aamodt Anne Hege, Alpers Iris, Ciccone Alfonso, Csiba Laszlo, Demotes Jacques, Korv Janika, Kurkowska-Jastrzebska Iwona, Dawson Jesse, Macleod Malcolm R., Ntaios George, Poli Sven, Milionis Haralampos, Ricci Stefano, Cenciarelli Silvia, Candelaresi Paolo, de Bruijn Sebastiaan F. T. M., Pathansali Rohan, Krishnan Kailash, Clarke Brian, Thomalla Götz, van der Worp H. Bart, PRECIOUS investigators
Dátum:2024
ISSN:2666-7762
Megjegyzések:Background: Infections and fever after stroke are associated with poor functional outcome or death. We assessed whether prophylactic treatment with anti-emetic, antibiotic, or antipyretic medication would improve functional outcome in older patients with acute stroke. Methods: We conducted an international, 2?2?2-factorial, randomised, controlled, open-label trial with blinded outcome assessment in patients aged 66 years or older with acute ischaemic stroke or intracerebral haemorrhage and a score on the National Institutes of Health Stroke Scale ? 6. Patients were randomly allocated (1:1) to metoclopramide (oral, rectal, or intravenous; 10 mg thrice daily) vs. no metoclopramide, ceftriaxone (intravenous; 2000 mg once daily) vs. no ceftriaxone, and paracetamol (oral, rectal, or intravenous; 1000 mg four times daily) vs. no paracetamol, started within 24 h after symptom onset and continued for four days. All participants received standard of care. The target sample size was 3800 patients. The primary outcome was the score on the modified Rankin Scale (mRS) at 90 days analysed with ordinal logistic regression and reported as an adjusted common odds ratio (an acOR < 1 suggests benefit and an acOR > 1 harm). This trial is registered (ISRCTN82217627). Findings: From April 2016 through June 2022, 1493 patients from 67 European sites were randomised to metoclopramide (n = 704) or no metoclopramide (n = 709), ceftriaxone (n = 594) or no ceftriaxone (n = 482), and paracetamol (n = 706) or no paracetamol (n = 739), of whom 1471 were included in the intention-to-treat analysis. Prophylactic use of study medication did not significantly alter the primary outcome at 90 days: metoclopramide vs. no metoclopramide (adjusted common odds ratio [acOR], 1.01; 95% CI 0.81?1.25), ceftriaxone vs. no ceftriaxone (acOR 0.99; 95% CI 0.77?1.27), paracetamol vs. no paracetamol (acOR 1.19; 95% CI 0.96?1.47). The study drugs were safe and not associated with an increased incidence of serious adverse events. Interpretation: We observed no sign of benefit of prophylactic use of metoclopramide, ceftriaxone, or paracetamol during four days in older patients with a moderately severe to severe acute stroke. Funding: This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No: 634809.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Fever
Infection
Intracerebral haemorrhage
Ischaemic stroke
Pneumonia
Stroke
Megjelenés:The Lancet Regional Health - Europe. - 36 (2024), p. 1-15. -
További szerzők:Sluis, Wouter M. Reinink, Hendrik Bath, Philip M. Woodhouse, Lisa J. Zweedijk, Berber van de Beek, Diederik Aamodt, Anne Hege Alpers, Iris Ciccone, Alfonso Csiba László (1952-) (neurológus, pszichiáter) Demotes-Mainard, Jacques Kõrv, Janika Kurkowska-Jastrzebska, Iwona Dawson, Jesse Macleod, Malcolm R. Ntaios, George Poli, Sven Milionis, Haralampos Ricci, Stefano Cenciarelli, Silvia Candelaresi, Paolo de Bruijn, Sebastiaan F. T. M. Pathansali, Rohan Krishnan, Kailash Clarke, Brian Thomalla, Götz van der Worp, H. Bart PRECIOUS investigators
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM046046
Első szerző:Diener, Hans-Christoph
Cím:Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH) : randomised, double-blind, placebo-controlled trial / Diener Hans-Christoph, Bogousslavsky Julien, Brass Lawrence M, Cimminiello Claudio, Csiba Laszlo, Kaste Markku, Leys Didier, Matias-Guiu Jordi, Rupprecht Hans-Jürgen, the MATCH Investigators
Dátum:2004
ISSN:0140-6736
Megjegyzések:Clopidogrel was superior to aspirin in patients with previous manifestations of atherothrombotic disease in the CAPRIE study and its benefit was amplified in some high-risk subgroups of patients. We aimed to assess whether addition of aspirin to clopidogrel could have a greater benefit than clopidogrel alone in prevention of vascular events with potentially higher bleeding risk. METHODS: We did a randomised, double-blind, placebo-controlled trial to compare aspirin (75 mg/day) with placebo in 7599 high-risk patients with recent ischaemic stroke or transient ischaemic attack and at least one additional vascular risk factor who were already receiving clopidogrel 75 mg/day. Duration of treatment and follow-up was 18 months. The primary endpoint was a composite of ischaemic stroke, myocardial infarction, vascular death, or rehospitalisation for acute ischaemia (including rehospitalisation for transient ischaemic attack, angina pectoris, or worsening of peripheral arterial disease). Analysis was by intention to treat, using logrank test and a Cox's proportional-hazards model. FINDINGS: 596 (15.7%) patients reached the primary endpoint in the group receiving aspirin and clopidogrel compared with 636 (16.7%) in the clopidogrel alone group (relative risk reduction 6.4%, [95% CI -4.6 to 16.3]; absolute risk reduction 1% [-0.6 to 2.7]). Life-threatening bleedings were higher in the group receiving aspirin and clopidogrel versus clopidogrel alone (96 [2.6%] vs 49 [1.3%]; absolute risk increase 1.3% [95% CI 0.6 to 1.9]). Major bleedings were also increased in the group receiving aspirin and clopidogrel but no difference was recorded in mortality. INTERPRETATION: Adding aspirin to clopidogrel in high-risk patients with recent ischaemic stroke or transient ischaemic attack is associated with a non-significant difference in reducing major vascular events. However, the risk of life-threatening or major bleeding is increased by the addition of aspirin.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Lancet. - 364 : 9431 (2004), p. 331-337. -
További szerzők:Bogousslavsky, Julien Brass, Lawrence M. Cimminiello, Claudio Csiba László (1952-) (neurológus, pszichiáter) Kaste, Markku Leys, Didier Matias-Guiu, Jordi Rupprecht, Hans-Jürgen the MATCH Investigators
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

4.

001-es BibID:BIBFORM067755
Első szerző:Kalincik, Tomas
Cím:Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis : a cohort study / Tomas Kalincik, J. William L. Brown, Neil Robertson, Mark Willis, Neil Scolding, Claire M. Rice, Alastair Wilkins, Owen Pearson, Tjalf Ziemssen, Michael Hutchinson, Christopher McGuigan, Vilija Jokubaitis, Tim Spelman, Dana Horakova, Eva Havrdova, Maria Trojano, Guillermo Izquierdo, Alessandra Lugaresi, Alexandre Prat, Marc Girard, Pierre Duquette, Pierre Grammond, Raed Alroughani, Eugenio Pucci, Patrizia Sola, Raymond Hupperts, Jeannette Lechner-Scott, Murat Terzi, Vincent Van Pesch, Csilla Rozsa, François Grand'Maison, Cavit Boz, Franco Granella, Mark Slee, Daniele Spitaleri, Javier Olascoaga, Roberto Bergamaschi, Freek Verheul, Steve Vucic, Pamela McCombe, Suzanne Hodgkinson, Jose Luis Sanchez-Menoyo, Radek Ampapa, Magdolna Simo, Tunde Csepany, Cristina Ramo, Edgardo Cristiano, Michael Barnett, Helmut Butzkueven, Alasdair Coles, MSBase Study Group
Dátum:2017
ISSN:1474-4422
Megjegyzések:BackgroundAlemtuzumab, an anti-CD52 antibody, is proven to be more efficacious than interferon beta-1a in the treatment of relapsing-remitting multiple sclerosis, but its efficacy relative to more potent immunotherapies is unknown. We compared the effectiveness of alemtuzumab with natalizumab, fingolimod, and interferon beta in patients with relapsing-remitting multiple sclerosis treated for up to 5 years.MethodsIn this international cohort study, we used data from propensity-matched patients with relapsing-remitting multiple sclerosis from the MSBase and six other cohorts. Longitudinal clinical data were obtained from 71 MSBase centres in 21 countries and from six non-MSBase centres in the UK and Germany between Nov 1, 2015, and June 30, 2016. Key inclusion criteria were a diagnosis of definite relapsing-remitting multiple sclerosis, exposure to one of the study therapies (alemtuzumab, interferon beta, fingolimod, or natalizumab), age 65 years or younger, Expanded Disability Status Scale (EDSS) score 6?5 or lower, and no more than 10 years since the first multiple sclerosis symptom. The primary endpoint was annualised relapse rate. The secondary endpoints were cumulative hazards of relapses, disability accumulation, and disability improvement events. We compared relapse rates with negative binomial models, and estimated cumulative hazards with conditional proportional hazards models.FindingsPatients were treated between Aug 1, 1994, and June 30, 2016. The cohorts consisted of 189 patients given alemtuzumab, 2155 patients given interferon beta, 828 patients given fingolimod, and 1160 patients given natalizumab. Alemtuzumab was associated with a lower annualised relapse rate than interferon beta (0?19 [95% CI 0?14?0?23] vs 0?53 [0?46?0?61], p<0?0001) and fingolimod (0?15 [0?10?0?20] vs 0?34 [0?26?0?41], p<0?0001), and was associated with a similar annualised relapse rate as natalizumab (0?20 [0?14?0?26] vs 0?19 [0?15?0?23], p=0?78). For the disability outcomes, alemtuzumab was associated with similar probabilities of disability accumulation as interferon beta (hazard ratio [HR] 0?66 [95% CI 0?36?1?22], p=0?37), fingolimod (1?27 [0?60?2?70], p=0?67), and natalizumab (0?81 [0?47?1?39], p=0?60). Alemtuzumab was associated with similar probabilities of disability improvement as interferon beta (0?98 [0?65?1?49], p=0?93) and fingolimod (0?50 [0?25?1?01], p=0?18), and a lower probability of disability improvement than natalizumab (0?35 [0?20?0?59], p=0?0006).InterpretationAlemtuzumab and natalizumab seem to have similar effects on annualised relapse rates in relapsing-remitting multiple sclerosis. Alemtuzumab seems superior to fingolimod and interferon beta in mitigating relapse activity. Natalizumab seems superior to alemtuzumab in enabling recovery from disability. Both natalizumab and alemtuzumab seem highly effective and viable immunotherapies for multiple sclerosis. Treatment decisions between alemtuzumab and natalizumab should be primarily governed by their safety profiles.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Lancet Neurology 16 : 4 (2017), p. 271-281. -
További szerzők:Brown, Jeremy William L. Robertson, Neil Willis, Mark Scolding, Neil Rice, Claire M. Wilkins, Alastair Pearson, Owen Ziemssen, Tjalf Hutchinson, Michael McGuigan, Christopher Jokubaitis, Vilija Spelman, Tim Horakova, Dana Havrdova, Eva Trojano, Maria Izquierdo, Guillermo Lugaresi, Alessandra Prat, Alexandre Girard, Marc Duquette, Pierre Grammond, Pierre Alroughani, Raed Pucci, Eugenio Sola, Patrizia Hupperts, Raymond Lechner-Scott, Jeannette Terzi, Murat Pesch, Vincent van Rózsa Csilla Grand'Maison, Francois Boz, Cavit Granella, Franco Slee, Mark Spitaleri, Daniele Olascoaga, Javier Bergamaschi, Roberto Verheul, Freek Vucic, Steve McCombe, Pamela Hodgkinson, Suzanne Sanchez-Menoyo, Jose Ampapa, Radek Simó Magdolna Csépány Tünde (1956-) (neurológus, pszichiáter) Ramo, Cristina Cristiano, Edgardo Barnett, Michael Butzkueven, Helmut Coles, Alasdair MSBase Study Group
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

5.

001-es BibID:BIBFORM005123
Első szerző:Kappos, Ludwig
Cím:Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis : a multicentre, randomised, double-blind, placebo-controlled phase IIb studye / Kappos L., Gold R., Miller D. H., Macmanus D. G., Havrdova E., Limmroth V., Polman C. H., Schmierer K., Yousry T. A., Yang M., Eraksoy M., Meluzinova E., Rektor I., Dawson K. T., Sandrock A. W., O'Neill G. N., BG-12 Phase IIb Study Investigators
Dátum:2008
Megjegyzések:Oral fumarate (BG00012) might have dual anti-inflammatory and neuroprotective eff ects. Our aim was to assess the efficacy and safety of BG00012 in patients with relapsing-remitting multiple sclerosis. Methods 257 patients, aged 18-55 years, with relapsing-remitting multiple sclerosis were randomly assigned to receive 120 mg once daily (n=64), 120 mg three times daily (n=64), or 240 mg three times daily (n=64) BG00012, or placebo (n=65) for 24 weeks. During an extension period of 24 weeks for safety assessment, patients treated with placebo received BG00012 240 mg three times daily. The primary endpoint was total number of new gadolinium enhancing (GdE) lesions on brain MRI scans at weeks 12, 16, 20, and 24. Additional endpoints included cumulative number of new GdE lesions (weeks 4-24), new or enlarging T2-hyperintense lesions, new T1-hypointense lesions at week 24, and annualised relapse rate. Analysis was done on the effi cacy-evaluable population. Safety and tolerability were also assessed. This study is registered with ClinicalTrials.gov, number NCT00168701. Findings Treatment with BG00012 240 mg three times daily reduced by 69% the mean total number of new GdE lesions from week 12 to 24 compared with placebo (1-4 vs 4-5, p<0-0001). It also reduced number of new or enlarging T2-hyperintense (p=0-0006) and new T1-hypointense p=0-014) lesions compared with placebo. BG00012 reduced annualised relapse rate by 32% (0-44 vs 0-65 for placebo; p=0-272). Adverse events more common in patients given BG00012 than in those given placebo included abdominal pain, flushing, and hot flush. Dose-related adverse events in patients on BG00012 were headache, fatigue, and feeling hot. Interpretation The anti-inflammatory effects and favourable safety profi le of BG00012 warrant further long-term phase III studies in large patient groups.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Lancet. - 372 : 9648 (2008), p. 1463-1472. -
További szerzők:Gold, Ralf Miller, David H. Macmanus, David G. Havrdova, Eva Limmroth, Volker Polman, Chris H. Schmierer, Klaus Yousry, Tarek A. Yang, Minhua Eraksoy, Mefkure Meluzinova, Eva Rektor, Ivan Dawson, Katherine T. Sandrock, Alfred W. O'Neill, Gilmore N. Csépány Tünde (1956-) (neurológus, pszichiáter) Csiba László (1952-) (neurológus, pszichiáter) BG-12 Phase IIb Study Investigators
Internet cím:elektronikus változat
DOI
Borító:

6.

001-es BibID:BIBFORM107109
035-os BibID:(scopus)85057212822 (wos)000450119300015
Első szerző:Kasner, Scott E.
Cím:Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source : a prespecified subgroup analysis from the NAVIGATE ESUS trial / Scott E. Kasner, Balakumar Swaminathan, Pablo Lavados, Mukul Sharma, Keith Muir, Roland Veltkamp, Sebastian F. Ameriso, Matthias Endres, Helmi Lutsep, Steven R. Messé, J. David Spence, Krassen Nedeltechev, Kanjana Perera, Gustavo Santo, Veronica Olavarria, Arne Lindgren, Shrikant Bangdiwala, Ashkan Shoamanesh, Scott D. Berkowitz, Hardi Mundl, Stuart J. Connolly, Robert G. Hart, NAVIGATE ESUS Investigators
Dátum:2018
ISSN:1474-4422 1474-4465
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Lancet Neurology. - 17 : 12 (2018), p. 1053-1060. -
További szerzők:Swaminathan, Balakumar Lavados, Pablo Sharma, Mukul Muir, Keith Veltkamp, Roland Ameriso, Sebastian F. Endres, Matthias Lutsep, Helmi Messé, Steven R. Spence, J. David Nedeltechev, Krassen Perera, Kanjana Santo, Gustavo Olavarria, Veronica Lindgren, Arne G. Bangdiwala, Shrikant I. Shoamanesh, Ashkan Berkowitz, Scott D. Mundl, Hardi Connolly, Stuart J. Hart, Robert G. Csiba László (1952-) (neurológus, pszichiáter) Oláh László (1967-) (neurológus) NAVIGATE ESUS Investigators
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

7.

001-es BibID:BIBFORM069440
Első szerző:Lublin, Fred
Cím:Oral fingolimod in primary progressive multiple sclerosis (INFORMS) : a phase 3, randomised, double-blind, placebo-controlled trial / Lublin Fred, Miller David H., Freedman Mark S., Cree Bruce A. C., Wolinsky Jerry S., Weiner Howard, Lubetzki Catherine, Hartung Hans-Peter, Montalban Xavier, Uitdehaag Bernard M. J., Merschhemke Martin, Li Bingbing, Putzki Norman, Liu Fonda C., Häring Dieter A., Kappos Ludwig, INFORMS study investigators
Dátum:2016
ISSN:0140-6736
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Lancet 387 : 10023 (2016), p. 1075-1084. -
További szerzők:Miller, David H. Freedman, Mark S. Cree, Bruce A. C. Wolinsky, Jerry S. Weiner, Howard Lubetzki, Catherine Hartung, Hans-Peter Montalbán, Xavier Uitdehaag, Bernard M. J. Merschhemke, Martin Li, Bingbing Putzki, Norman Liu, Fonda C. Häring, Dieter A. Kappos, Ludwig Csiba László (1952-) (neurológus, pszichiáter) INFORMS study investigators
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

8.

001-es BibID:BIBFORM036324
Első szerző:Segal, Benjamin M.
Cím:Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis : a phase II, double-blind, placebo-controlled, randomised, dose-ranging study / Segal Benjamin M., Constantinescu Cris S., Raychaudhuri Aparna, Kim Lilianne, Fidelus-Gort Rosanne, Kasper Lloyd H., on behalf of the Ustekinumab MS Investigators
Dátum:2008
ISSN:1474-4422
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Lancet Neurology. - 7 : 9 (2008), p. 796-804. -
További szerzők:Constantinescu, Cris S. Raychaudhuri, Aparna Kim, Lilianne Fidelus-Gort, Rosanne Kasper, Lloyd H. Csiba László (1952-) (neurológus, pszichiáter) on behalf of the Ustekinumab MS Investigators
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1 
Corvina könyvtári katalógus v8.2.27 © 2023 Monguz kft. Minden jog fenntartva.